戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hs were 26.3% vs 22.8% (P < .001, unadjusted Kaplan-Meier survival analysis).
2 n 432 RBD patients with available data using Kaplan-Meier survival analysis.
3  stepwise Cox proportional hazards model and Kaplan-Meier survival analysis.
4 ngitudinal shedding rates were determined by Kaplan-Meier survival analysis.
5  Median wait time to kidney transplant using Kaplan-Meier survival analysis.
6 e analyzed using Cox proportional hazard and Kaplan-Meier survival analysis.
7 he prognostic effects of hub-genes using the Kaplan-Meier survival analysis.
8 x proportional hazards regression models and Kaplan-Meier survival analysis.
9   Time to glaucoma treatment escalation in a Kaplan-Meier survival analysis.
10 tims after the index PPN submission, we used Kaplan-Meier survival analysis.
11 bilities of AC, AH, and AHC were compared by Kaplan-Meier survival analysis.
12  evaluated using multivariate regression and Kaplan-Meier survival analysis.
13 icular cascade stage at a specific time with Kaplan-Meier survival analysis.
14 rvival was evaluated for up to 9 weeks using Kaplan-Meier survival analysis.
15 g a more clinically informative picture than Kaplan-Meier survival analysis.
16                  Results were assessed using Kaplan-Meier survival analysis.
17 2 years were 6% and 15%, respectively, using Kaplan-Meier survival analysis.
18 ow vision and blindness were estimated using Kaplan-Meier survival analysis.
19  receiver operator characteristic curves and Kaplan-Meier survival analysis.
20     Survival probabilities were estimated by Kaplan-Meier survival analysis.
21        Recurrence rates were evaluated using Kaplan-Meier survival analysis.
22                Graft success was assessed by Kaplan-Meier survival analysis.
23 t contrast-enhanced CT was analyzed by using Kaplan-Meier survival analysis.
24  overall survival (OS) were calculated using Kaplan-Meier survival analysis.
25 urvival in the 3 groups was calculated using Kaplan-Meier survival analysis.
26           We calculated seroconversion using Kaplan-Meier survival analysis.
27 ventricular pacing quartiles with the use of Kaplan-Meier survival analysis.
28 rs were related to patient survival by using Kaplan-Meier survival analysis.
29 s in recipient subgroups were compared using Kaplan-Meier survival analysis.
30 model parameters, fixed-point mortality, and Kaplan-Meier survival analysis.
31                                      Using a Kaplan-Meier survival analysis, 1-, 5-, and 10-year dise
32                                           In Kaplan-Meier survival analysis, all-cause mortality amon
33                                              Kaplan-Meier survival analysis analyzed time to corneal
34 ay model, and posttransplant mortality using Kaplan-Meier survival analysis and a multivariate propor
35  >/=80% of HIV QIs and mortality rates using Kaplan-Meier survival analysis and adjusted Cox proporti
36                                              Kaplan-Meier survival analysis and ANOVA were performed.
37 ine loss of function in PROS1 was evident in Kaplan-Meier survival analysis and appeared to persist t
38 rgan Sharing dataset from 1994 to 1999 using Kaplan-Meier survival analysis and Cox modeling.
39     Risk of developing NVG was assessed with Kaplan-Meier survival analysis and Cox proportional haza
40                                     Applying Kaplan-Meier survival analysis and Cox proportional haza
41                                              Kaplan-Meier survival analysis and Cox proportional haza
42 esting before escalation were analyzed using Kaplan-Meier survival analysis and Cox proportional haza
43 ing, and thromboembolism were examined using Kaplan-Meier survival analysis and Cox proportional haza
44                                              Kaplan-Meier survival analysis and Cox proportional haza
45                                              Kaplan-Meier survival analysis and Cox proportional haza
46 ive-year overall survival was examined using Kaplan-Meier survival analysis and Cox proportional haza
47  of recurrent GBM tumors were analyzed using Kaplan-Meier survival analysis and Cox proportional haza
48                                              Kaplan-Meier survival analysis and Cox proportional haza
49                                              Kaplan-Meier survival analysis and Cox proportional haza
50                                              Kaplan-Meier survival analysis and Cox regression analys
51 with days 1 to 12 after the first dose using Kaplan-Meier survival analysis and generalized linear mo
52 initially healthy fellow eyes assessed using Kaplan-Meier survival analysis and log-rank test compari
53                                 Importantly, Kaplan-Meier survival analysis and log-rank test reveale
54 0), or poor (ypT3-4 or N+) response by using Kaplan-Meier survival analysis and multivariate Cox prop
55 oma skin cancers), which was evaluated using Kaplan-Meier survival analysis and proportional hazards
56                                              Kaplan-Meier survival analysis and risk factors associat
57                                              Kaplan-Meier survival analysis and the log-rank test wer
58 stic factors of disease-free survival (DFS), Kaplan-Meier survival analysis and univariable and multi
59                                 We conducted Kaplan-Meier survival analysis and used Cox proportional
60  overall survival (OS) were calculated using Kaplan-Meier survival analysis, and differences between
61 sis performed include the Fisher exact test, Kaplan-Meier survival analysis, and log-rank test.
62 e to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for fir
63  Corneal graft survival was calculated using Kaplan-Meier survival analysis, and survival distributio
64 etection of progression was compared using a Kaplan-Meier survival analysis, and the agreement of RPA
65                                              Kaplan-Meier survival analysis assessed overall survival
66                                   Univariate Kaplan-Meier survival analysis assessed the difference i
67                                              Kaplan-Meier survival analysis assessed the probability
68                                              Kaplan-Meier survival analysis at follow-up demonstrated
69                                        Using Kaplan-Meier survival analysis based on HCC databases, w
70 bability of surgical success at 2 years with Kaplan-Meier survival analysis be used as the primary ef
71                              A case-control, Kaplan-Meier survival analysis between HPS patients and
72 oring with matched pairs was used to perform Kaplan-Meier survival analysis comparing patients who un
73                                     Standard Kaplan-Meier survival analysis confirmed the prognostic
74                                      We used Kaplan-Meier survival analysis, Cox proportional hazards
75                                              Kaplan-Meier survival analysis demonstrated 100% 1-year
76                                            A Kaplan-Meier survival analysis demonstrated no statistic
77                                          The Kaplan-Meier survival analysis demonstrated significant
78                                              Kaplan-Meier survival analysis demonstrated significantl
79                                              Kaplan-Meier survival analysis demonstrated that nuclear
80                                              Kaplan-Meier survival analysis did not demonstrate a dif
81                                              Kaplan-Meier survival analysis did not demonstrate a sig
82                                              Kaplan-Meier survival analysis estimated a better globe
83                                              Kaplan-Meier survival analysis estimated the incidence o
84                                            A Kaplan-Meier survival analysis evaluated survival experi
85                                              Kaplan-Meier survival analysis failed to demonstrate an
86                                      Indeed, Kaplan-Meier survival analysis for patients with pancrea
87                                            A Kaplan-Meier survival analysis gives a median time of 40
88                           Cox regression and Kaplan-Meier survival analysis identified that amplifica
89 sential biomedical analysis tasks, including Kaplan-Meier survival analysis in oncology and genome-wi
90 tween propensity score matched cohorts using Kaplan-Meier survival analysis, including hazard ratio (
91                                            A Kaplan-Meier survival analysis indicated a significantly
92                                 Importantly, Kaplan-Meier survival analysis indicated that elevated K
93                     Stratified at the means, Kaplan-Meier survival analysis indicated that lower valu
94                                              Kaplan-Meier survival analysis indicated that the isolat
95                                              Kaplan-Meier survival analysis is available, including c
96 y of CCUR within 72 h was assessed using the Kaplan-Meier survival analysis log-rank test.
97 late molecular status with clinical outcome, Kaplan-Meier survival analysis of 94 consecutive patient
98 n investigated the importance of CASP4 using Kaplan-Meier survival analysis of glioma patients.
99                      We recently performed a Kaplan-Meier survival analysis of naked mole-rats (Heter
100                                            A Kaplan-Meier survival analysis of the cohort found that
101                                              Kaplan-Meier survival analysis of the primary end point
102                                   Pan-cancer Kaplan-Meier survival analysis on 21 human cancer types
103  was predictive for a lower survival using a Kaplan-Meier survival analysis (P < 0.001).
104 mulative survival, 63 months vs not reached, Kaplan-Meier survival analysis; P <.03, log-rank test).
105                                              Kaplan-Meier survival analysis predicts an 82% survival
106                                              Kaplan-Meier survival analysis revealed 1-year, 10-year,
107                                              Kaplan-Meier survival analysis revealed a global success
108                                              Kaplan-Meier survival analysis revealed that high G9a ex
109                                              Kaplan Meier survival analysis showed significantly shor
110                                            A Kaplan-Meier survival analysis showed a 44% reduction in
111                                              Kaplan-Meier survival analysis showed a reduction of 48
112                                            A Kaplan-Meier survival analysis showed a significant diff
113                            More importantly, Kaplan-Meier survival analysis showed a significant surv
114                                              Kaplan-Meier survival analysis showed a significantly hi
115                                              Kaplan-Meier survival analysis showed a significantly hi
116                                              Kaplan-Meier survival analysis showed an 89% cumulative
117                                              Kaplan-Meier survival analysis showed better survival in
118                                              Kaplan-Meier survival analysis showed better survival ra
119                                              Kaplan-Meier survival analysis showed combined (P = 0.00
120                                              Kaplan-Meier survival analysis showed decreased 5-year d
121                                              Kaplan-Meier survival analysis showed increased risk of
122                           Propensity-matched Kaplan-Meier survival analysis showed no difference in g
123                                              Kaplan-Meier survival analysis showed similar cumulative
124 th those without pouchitis (72% vs. 45%) and Kaplan-Meier survival analysis showed that allele 2 carr
125                                              Kaplan-Meier survival analysis showed that different sut
126                                          The Kaplan-Meier survival analysis showed that IMT significa
127                                            A Kaplan-Meier survival analysis showed that progression w
128                                              Kaplan-Meier survival analysis showed that subsequent to
129                                              Kaplan-Meier survival analysis showed that this differen
130                                              Kaplan-Meier survival analysis showed that whereas all L
131 ng multivariable Cox regression analysis and Kaplan-Meier survival analysis, taking into account age,
132                                           In Kaplan-Meier survival analysis, TCC patients with >20% p
133                                        Using Kaplan-Meier survival analysis, the estimated annual eve
134                                           By Kaplan-Meier survival analysis, the first versus the fir
135                                           By Kaplan-Meier survival analysis, the only significant pre
136                                           In Kaplan-Meier survival analysis, the risk of developing D
137                                           On Kaplan-Meier survival analysis there was a nonsignifican
138                                      We used Kaplan-Meier survival analysis to adjust for censorship
139 tional Health Interview Survey (NHIS), using Kaplan-Meier survival analysis to estimate cumulative pr
140  study period were compared using unadjusted Kaplan-Meier survival analysis to estimate risk of and t
141                                      We used Kaplan-Meier survival analysis to estimate time to first
142  applied Cox proportional hazards models and Kaplan-Meier survival analysis to evaluate survival outc
143                                      We used Kaplan-Meier survival analysis to examine the distributi
144 was used to compare demographic factors, and Kaplan-Meier survival analysis used to compare 5-year OS
145                                              Kaplan Meier survival analysis was done looking at trans
146 tive primary venographic patency by means of Kaplan-Meier survival analysis was 55% at 6 months and 5
147                                            A Kaplan-Meier survival analysis was also conducted.
148                                              Kaplan-Meier survival analysis was also performed to tes
149                                            A Kaplan-Meier survival analysis was conducted to compare
150                                            A Kaplan-Meier survival analysis was done for incident epi
151                                              Kaplan-Meier survival analysis was performed for aggress
152                                            A Kaplan-Meier survival analysis was performed on the basi
153                                              Kaplan-Meier survival analysis was performed to estimate
154                                              Kaplan-Meier survival analysis was performed to examine
155                                              Kaplan-Meier survival analysis was performed using a tum
156                                              Kaplan-Meier survival analysis was performed, with renal
157                                              Kaplan-Meier survival analysis was used to assess genoty
158                                              Kaplan-Meier survival analysis was used to assess reoper
159 he BCLC and HKLC stages were identified, and Kaplan-Meier survival analysis was used to compare patie
160                                              Kaplan-Meier survival analysis was used to compare recur
161                                          The Kaplan-Meier survival analysis was used to determine reo
162 es were evaluated by proteome microarray and Kaplan-Meier survival analysis was used to determine sur
163                                            A Kaplan-Meier survival analysis was used to determine the
164                                              Kaplan-Meier survival analysis was used to determine the
165 d 2022 and observed until December 30, 2022, Kaplan-Meier survival analysis was used to determine the
166                                              Kaplan-Meier survival analysis was used to estimate surv
167                                              Kaplan-Meier survival analysis was used to estimate the
168                                              Kaplan-Meier survival analysis was used to evaluate the
169                                              Kaplan-Meier survival analysis was used to plot genotype
170                                              Kaplan-Meier survival analysis was utilized to compare m
171                                        Using Kaplan-Meier survival analysis, we compared the survival
172                                        Using Kaplan-Meier survival analysis, we estimated that the me
173                                        Using Kaplan-Meier survival analysis, we found 30-day mortalit
174         Outcomes for autoislet recipients by Kaplan-Meier survival analysis were compared with those
175 edictors of LMNA mutation carrier status and Kaplan-Meier survival analysis were performed.
176                  Cox regression modeling and Kaplan-Meier survival analysis were used to estimate the
177                           Cox regression and Kaplan-Meier survival analysis were used to evaluate tim
178  Surgical success rates were estimated using Kaplan-Meier survival analysis, whereas comparisons betw
179                                              Kaplan-Meier survival analysis, which takes varying leng
180                                              Kaplan-Meier survival analysis with a log-rank test was
181 -to-first-event analysis was performed using Kaplan-Meier survival analysis with hazard ratio and 95%
182                                              Kaplan-Meier survival analysis with log-rank comparison
183                                              Kaplan-Meier survival analysis with log-rank testing was
184 ormed using chi(2) analysis, Student t test, Kaplan-Meier survival analysis with the log-rank test, a
185 rtality risk categories were evaluated using Kaplan-Meier survival analysis, with both dichotomous (R

 
Page Top